In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 479-486

  Wang, Julie L ^a   Oya, Shunichi ^a   Parhi, Ajit K ^a   Lieberman, Brian P ^a   Ploessl, Karl ^a   Hou, Catherine ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain imaging; Parkinson's disease; Radioligand; SERT; VMAT2

Indexed keywords

2 [2' [(DIMETHYLAMINO)METHYL] 4' (3' FLUOROPROPOXY)PHENYLTHIO]BENZENAMINE F 18; 2 HYDROXY 3 ISOBUTYL 9 (3 FLUOROPROPOXY) 10 METHOXY 1,2,3,4,6,7 HEXAHYDRO 11BH BENZO[A]QUINOLIZINE F 18; AV 133; CHLORAMPHETAMINE; DOPAMINE TRANSPORTER; N (3' IODOPROPEN 2' YL) 2 BETA CARBOMETHOXY 3 BETA (4 CHLOROPHENYL)TROPANE I 125; OXIDOPAMINE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; HYPOTHALAMUS; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RAT; SEROTONINERGIC NERVE CELL; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; MALE; P-CHLOROAMPHETAMINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOACTIVE TRACERS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SUBSTRATE SPECIFICITY; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77952511883     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.01.006     Document Type: Article

References (41)

1. Davidson J.R. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2009, 70(Suppl 2):25-31.
2. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007, 41(3-4):189-206.
3. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 2001;3:232-5.
4. Thase M.E. Are SNRIs More Effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 2008, 41:58-85.
5. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 2009, 16:652-657.
6. Kugaya A., Sanacora G., Staley J.K., Malison R.T., Bozkurt A., Khan S., et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004, 56:497-502.
7. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161:826-835.
8. Ruhe H.G., Booij J., v Weert H.C., Reitsma J.B., Franssen E.J., Michel M.C., et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009, 34:999-1010.
9. Albin R.L., Koeppe R.A., Bohnen N.I., Wernette K., Kilbourn M.A., Frey K.A. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008, 28:441-444.
10. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007, 14:523-528.
11. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
12. Thomas A.J., Hendriksen M., Piggott M., Ferrier I.N., Perry E., Ince P., et al. A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathol Appl Neurobiol 2006, 32:296-303.
13. Caretti V., Stoffers D., Winogrodzka A., Isaias I.U., Costantino G., Pezzoli G., et al. Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm 2008, 115:721-729.
14. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003, 60:1223-1229.
15. Azmitia E.C., Nixon R. Dystrophic serotonergic axons in neurodegenerative diseases. Brain Res 2008, 1217C:185-194.
16. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
17. Garg S., Thopate S.R., Minton R.C., Black K.W., Lynch A.J. Garg PK. 3-Amino-4-(2-((4-[18F]fluorobenzyl)methylamino)methylphenylsulfanyl)benzonitrile, an F-18 fluorobenzyl analogue of DASB: synthesis, in vitro binding, and in vivo biodistribution studies. Bioconjug Chem 2007, 18:1612-1618.
18. Huang Y.Y., Huang W.S., Chu T.C., Shiue C.Y. An improved synthesis of 4-[18F]-ADAM, a potent serotonin transporter imaging agent. Appl Radiat Isot 2009, 67:1063-1067.
19. Jarkas N., Voll R.J., Williams L., Votaw J.R., Owens M., Goodman M.M. Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2?-amino-4?-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands. J Med Chem 2008, 51:271-281.
20. Ma K.H., Huang W.S., Kuo Y.Y., Peng C.J., Liou N.H., Liu R.S., et al. Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. Neuroimage 2009, 45:687-693.
21. 18F]ACF (2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J Med Chem 2002, 45:4716-4723.
22. Plisson C., Stehouwer J.S., Voll R.J., Howell L., Votaw J.R., Owens M.J., et al. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4?-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent. J Med Chem 2007, 50:4553-4560.
23. Parhi A.K., Wang J.L., Oya S., Choi S.R., Kung M.P., Kung H.F. 2-(2?-((dimethylamino)methyl)-4?-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents. J Med Chem 2007, 50:6673-6684.
24. Wang J.L., Parhi A.K., Oya S., Lieberman B., Kung M.P., Kung H.F. 2-(2?-((dimethylamino)methyl)-4?-(3-[(18)F]fluoropropoxy)-phenylthio)benze namine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol 2008, 35:447-458.
25. Wang J.L., Parhi A.K., Oya S., Lieberman B., Kung H.F. In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2?-((dimethylamino)methyl)-4?-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter. J Nucl Med 2009, 50:1509-1517.
26. Takeuchi Y., Sawada T., Blunt S., Jenner P., Marsden C.D. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res 1991, 562:301-305.
27. Zhang K., Davids E., Tarazi F.I., Baldessarini R.J. Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res 2002, 137:135-138.
28. Stachowiak M.K., Bruno J.P., Snyder A.M., Stricker E.M., Zigmond M.J. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res 1984, 291:164-167.
29. Molina-Holgado E., Dewar K.M., Descarries L., Reader T.A. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6-hydroxydopamine. J Pharmacol Exp Ther 1994, 270:713-721.
30. Luthman J., Bolioli B., Tsutsumi T., Verhofstad A., Jonsson G. Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res Bull 1987, 19:269-274.
31. Goswami R., Ponde D.E., Kung M.P., Hou C., Kilbourn M.R., Kung H.F. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006, 33:685-694.
32. Kilbourn M.R., Hockley B., Lee L., Hou C., Goswami R., Ponde D.E., et al. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 2007, 34:233-237.
33. Kung M.P., Hou C., Goswami R., Ponde D.E., Kilbourn M.R., Kung H.F. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET Imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007, 34:239-246.
34. Boileau I., Rusjan P., Houle S., Wilkins D., Tong J., Selby P., et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?. J Neurosci 2008, 28:9850-9856.
35. Kung M.P., Hou C., Lieberman B.P., Oya S., Ponde D.E., Blankemeyer E., et al. In Vivo Imaging of {beta}-Cell Mass in Rats Using 18F-FP-(+)-DTBZ: A Potential PET Ligand for Studying Diabetes Mellitus. J Nucl Med 2008, 49:1171-1176.
36. Harris P.E., Ferrara C., Barba P., Polito T., Freeby M., Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med 2008, 86:5-16.
37. Saisho Y., Harris P.E., Butler A.E., Galasso R., Gurlo T., Rizza R.A., et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 2008, 39:543-551.
38. Kung M.P., Essman W.D., Frederick D., Meegalla S., Goodman M., Mu M., et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995, 20:316-324.
39. Choi S.R., Hou C., Oya S., Mu M., Kung M.P., Siciliano M., et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 2000, 38:403-412.
40. 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem 2000, 43:3103-3110.
41. Soghomonian J.J., Doucet G., Descarries L. Serotonin innervation in adult rat neostriatum. I. Quantified regional distribution. Brain Res 1987, 425:85-100.